**Study 1: Dose Proportionality**

- Assessed for eligibility: N=56
  - Excluded: N=28
  - Randomised: N=30
    - Received treatment: N=30
      - Withdrew consent: N=1
  - Analysed
    - Safety population: N=30
    - PK population: N=29

**Study 2: Bioequivalence**

- Assessed for eligibility: N=48
  - Excluded: N=18
  - Randomised: N=30
  - Received treatment: N=30
  - Analysed
    - Safety population: N=30
    - PK population: N=30